Damora Therapeutics, Inc. Ordinary Shares (DMRA) Stock Price
DMRAStock
$29.00
Market Cap$1.79B
P/E—
PEG Ratio—
Div yield—
Beta-4.54
DMRA Share Price Chart
Favorite Metrics
Price vs S&P 500 (4W)-0.00%
VGM Score56.57
DMRA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.37 | -$0.39 | -5.41%(-$0.02) | |
| Q3 2025 | — | -$2.36 | — |
DMRA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.31
4.27
4.31
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DMRADamora Therapeutics, Inc. Ordinary Shares | — | — | C | $29.00 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Damora Therapeutics, Inc. Ordinary Shares
Damora Therapeutics develops biologics for calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant unmet medical need for disease-modifying treatments. The company's pipeline includes DMR-001, DMR-002, DMR-003, and GB3226, designed to provide broad mutation coverage in hematologic disorders.